Neoadjuvant targeted therapy for ameloblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the effectiveness of preoperative targeted therapy using dabrafenib and trametinib in patients with conventional ameloblastoma that have the BRAF V600E mutation. The primary objectives are to determine the proportion of patients who can undergo mandibular preservation surgery instead of segmental resection after treatment, and to assess the resectability of initially non-radically resectable cases. Secondary objectives include evaluating radiological and pathological responses, local recurrence-free survival, and the safety and feasibility of the treatment in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18-65 years;
2. Diagnosed with solid/multicystic type ameloblastoma with confirmed BRAF V600E mutation by next-generation sequencing (NGS);
3. Requires mandibular segmental resection at diagnosis, confirmed by two or more chief physicians;
4. No distant metastasis or malignancy;
5. ECOG score 0-1;
6. Willing to undergo surgery after induction therapy;
7. No significant contraindications to MEK and BRAF inhibitors;
8. Major organ function meets the following standards:

   1. Hematological: WBC ≥ 4.0×10\^9/L, ANC ≥ 1.5×10\^9/L, PLT ≥ 100×10\^9/L, Hb ≥ 90g/L (no transfusion or blood products, no use of G-CSF or other hematopoietic stimulants within 14 days);
   2. Biochemical: Serum albumin ≥ 3.0 g/dL, TBIL ≤ 1.5×ULN, ALT/AST ≤ 2.5×ULN, BUN/CRE ≤ 1.5×ULN or creatinine clearance rate ≥ 60 ml/min;
   3. Coagulation: INR or PT ≤ 1.5×ULN (anticoagulant-treated subjects must have PT within the intended range);
9. Women of childbearing age must use effective contraception, have a negative pregnancy test within 7 days before enrollment, and agree to use effective contraception during the study and for 16 weeks after the last dose of trametinib and dabrafenib. Male subjects with partners of childbearing age must use effective contraception during the study and for 16 weeks after the last dose of trametinib and dabrafenib.
10. Voluntary participation with signed informed consent, good compliance, and cooperation for follow-up.

Exclusion Criteria:

1. Previous use of dabrafenib, trametinib, or other BRAF/MEK inhibitors;
2. Active autoimmune diseases (stable conditions not requiring systemic immunosuppression allowed);
3. Congenital or acquired immunodeficiency (e.g., HIV), active hepatitis B (HBV-DNA ≥ 10\^4 copies/ml), or hepatitis C (positive HCV antibody and HCR-RNA above the detection limit);
4. Known allergy to study drugs or their excipients, or severe allergic reactions to other monoclonal antibodies or targeted drugs;
5. Myocardial infarction, severe/unstable angina, NYHA class II or higher heart failure, significant arrhythmias, or symptomatic congestive heart failure within 6 months before enrollment;
6. Live vaccination within 4 weeks before the first dose of study drugs (inactivated virus vaccines allowed for seasonal flu, but live attenuated intranasal vaccines not allowed);
7. History of allogeneic organ or hematopoietic stem cell transplantation;
8. Known history of substance abuse or drug addiction;
9. Pregnant or breastfeeding women;
10. Diagnosed with any other tumors within 5 years before the study, except for locally treatable and cured basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, ductal carcinoma in situ, papillary thyroid carcinoma, and benign tumors;
11. Other severe physical or mental diseases or laboratory abnormalities that may increase the risk of participation or interfere with study results, deemed unsuitable for participation by the investigator.

Where it's running

• Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: CAO Wei, PHD;MD — Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
• Study coordinator: ZHAO Zhang
• Email: zaidezaidezz@hotmail.com
• Phone: +86 15150104115

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant therapy with encorafenib plus cetuximab N01 and mFOLFOX6 in locally advanced BRAF V600E-mutant colorectal cancer

  This trial tests a targeted, pre-surgery treatment to see if it improves the chance of long-term control in adults with locally advanced BRAF V600E-mutant colorectal cancer.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07789210

• Using virtual planning to guide jaw tumor removal and reconstruction with bone from the hip

  This project tries CT-guided virtual surgical planning to help surgeons get clear margins and rebuild the jaw in people with segmental mandibular ameloblastoma.

  Recruiting Alexandria University · Alexandria, Alexandria Governorate · NCT07306962

• Combination treatment for localized colon or upper rectum cancer with BRAF mutation

  This study is testing a combination treatment of encorafenib and cetuximab for patients with localized colon or upper rectal cancer that has a specific BRAF mutation to see if it helps before surgery.

  Recruiting Phase 2 Federation Francophone de Cancerologie Digestive · Paris · NCT05706779

• Collecting data from patients with BRAFV600E-mutated metastatic colorectal cancer

  This study is collecting information and samples from patients with a specific type of metastatic colorectal cancer to see how well different treatments work and what factors affect their outcomes.

  Recruiting at 27 sites Unicancer · Avignon and 44 other locations · NCT05639413

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.